Furthermore, MGA012 enhances MGD007-mediated CTL activity and interferon gamma release upon exposure to gpA33-positive CRC and T cells, while MGD007 anti-tumor activity in preclinical mouse models is enhanced upon combination with anti-PD-1. Here, PDCD1 is linked to neoplasm.